September 20, 2017

INO-5150 Triggers Immune Responses, Delays Progression of Prostate Cancer That Returns, Trial Shows

News

The immunotherapy INO-5150 has shown promise as a treatment for prostate cancer that returns after surgery, according to a Phase 1b clinical trial. Inovio Pharmaceuticals’ cancer vaccine generated immune responses in ... Read more

November 19, 2014November 19, 2014

Inovio Pharmaceuticals Will Independently Develop Prostate Cancer Immunotherapy

News

Inovio Pharmaceuticals, Inc. has announced that it has finished a 2013 licensing agreement with Roche to co-develop INO-5150, Inovio’s investigational drug targeting prostate cancer. Furthermore, both companies will no longer collaborate ... Read more